DengueVrsEllagic Acid & Ferric Carboxymaltose: *InSilico*

Mr. Chandra Sekhar Tripathy1, Dr. Anil Kumar2, Dr. Santosh Kumar Behera1, Muhammad Akram2, Dr. Asadollah Asadi3, Dr. Arash Abdolmaleki4, Mr. Amir Mohammad Ostovar-Abarghoee5, Easter Khura6, Pabitra Kumar Mohanta1, Santanu Kumar Budhia7, Dr. Deepak Bhattacharya11

1M.Sc., I.C.M.R.-Regional Medical Research Centre, Bhubaneswar, Odisha, India
2Principal Scientist & Head, Division of Design of Experiments I.C.A.R.-I.A.S.R.I., Library Avenue, New Delhi, India
3Scientist Grade II, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat, India
4Professor, BEMS, M. Phil, Ph.D. Chairperson, Department of Eastern Medicine, Government Collage University, Faisalabad, Pakistan
5Associate Professor, Department of Biology, University of Mohaghegh Ardabili, Iran
6Assistant Professor, Animal Physiology, Department of Biophysics, University of Mohaghegh Ardabili, Faculty of Advanced Technologies, Iran
7Department of Biology, University of Mohaghegh Ardabili, Iran
8M.Sc (nursing), Vice Principal, School of Nursing, Raual, Bihar, India
9MD (Ay), Govt Drug Inspector; Registrar Ay Council; Principal, IGMMC & Hospital, H-2/58, SS Enclave, Khandagiri, Bhubaneswar-751030, Odisha, India
10BA; Traditional Ayurvedacharya, Nagharen Temple Rd, Baabjee Padaa, Balangir, Odisha, India
11Ph. D, Cancer Nursing and end of life stage care, Sri Radha Krishna RaasMandir, KedarGouri Road, Bhubaneswar–751002, Odisha, India

**Backgrounds:** Dengue viruses are transmitted to humans via mosquito bites from infected Aedes species (Aedesaegypti or Aedesalbopictus). Dengue fever affects over half of the world's population, or about 4 billion people. Dengue fever is a common cause of sickness in high-risk settings. **Methods:** In the current study two serotypes of Dengue viruses namely DENV1 and DENV2 taken for the study. Here two important compounds namely Ellagic acid and Ferric Carboxymaltose chosen for the targets to be inhibited. In silico docking approach performed to dock the two compounds against the DENV1 and DENV2 viruses of Dengue. Autodock 4.2 tool chosen for the docking purpose. **Results:** Dengue i.e., DENV-1 & 2 indicate excellent biding property with Ellagic Acid & Ferric Carboxymaltose of the order -6.02 kcal/mol & -6.9 kcal/mol, respectively. Either are hematinic; pregnancy safe; non-toxic; complete synergy between either vis-à-vis virus targets/bindings sites; with supportive therapies; etc. Novel. It was found that, the Ellagic acid is more effective for DENV1 virus and Ferric kcal/mol, respectively. **Conclusions:** It can be stated that, these two drugs can be better approach for future study against the Dengue viruses and expected drug candidates.

**Keywords:** Dengue; Ellagic Acid; Ferric Carboxymaltose; InSilico; Synergistic.

**INTRODUCTION**

Dengue (Spanish phone) nomenclatured as the acronym DENV wherein DEN = dengu/i & V = virus. It has 1-4 serotypes. All are self limitingfyphis of the *Flaviviridae* family [1]; & yellow. Mutates in nature and hence presents inter-continental or even intra-sub continental genetic variations [2] longitudinal and or latitudinal. Are arbo-virus (Ar = arthropod & Bo = borne) as they are vectored by the arthropods-mosquito (*Aedes* [3 spp]) which are abundant common carriers of poly viruses (tropo-equatorial belts). DENVs are positive, single-strand RNA, enveloped in 3 lipids coats, limited by 11.5kD (= medium range heavy); icosahedral. Serotype 1 & 2 are pathogenic. Clinically, DENV-1 is marked with red eyes. DENV-2 is marked by lower platelet count. Either with shooting pyrexia; blistering rash (torso either side); arthralgia; myalgia; debilitating headache (difficulty in keeping eyes open); plummeting platelet count (thrombocctopenia); hemorrhage &falling hematocrit; shock (O2 insufficiency in cerebral parenchyma & the coronary) [3]. DENV-3 & 4 are near nonpathogenic and are reported few and far between. Symptoms (DENV-1&2) manifests about 5th-6th day and wane by the 10th day and wane by the 10th...
limiting). There are no therapies save & except supportive (paracetamol) & symptomatic redress of the secondary pathologies (common) and the response pathologies (individual basis). Most cases respond. Grave prognosis is associated with co-morbidities. However, (i) decreasing RBC count & related phenomenon (ii) plummeting platelet count (iii) hemorrhage. In pandemic covid DENV is a sure candidate to because syndemic that complicate normal prognosis towards grave. All this necessitates search for specific, safe, therapeutics, which thus far has been conspicuous by absence. However, drug discovery is fraught with pitfalls & cost overruns. And whereas, computational pre-modeling cuts costs; saves time; averts many a pitfalls and serves society better. In-silico route has therefore been the choice path [4]. And very recently used by Behera et al., to screen-evaluate 56 commercially available drug moietyes that have been pan globally re-purposed for Covid combat [5]. In this communication we report (A) Ellagic acid EA (B) Ferriccarboxymaltose FC as insilico study results vis-à-vis DENV-1 & 2, respectively. Either offer excellent binding affinity and other indicators. EA since 2004 has continuously & variedly been reported to be anti-virus [6, 7]. FC not till this communication. Furthermore, these two compounds are physiology/pregnancy safe (jointly with paracetamol) and offer scope for inter-compound (even multi drug) complementarities cum supplementing use with synergistic therapeutic effect. Novel, vis-à-vis DENV.

**MATERIAL & METHODS**

**Target Serotypes**

Only 2 serotypes of Dengue virus DENV-1 and DENV-2. Others are less pathogenic and also not prevalent.

**Structure Selection**

Protein structures of the either serotypes have been selected from the PDB(Protein Data Bank) database [8].

**Drug Selection and Structure Finding**

(i) Ellagic acid and (ii) Ferric carboxymaltose are the two drug candidate compounds (note-i).

The respective structures were downloaded from PubChem Database [9] in SDF file format and converted into .pdb format in Discovery studio software.

**Binding Sites Selection**

CASTP web server has been used to find the binding sites of the protein structures [10].

**Serotypes Structure Selection**

Chain A of the PDB structure/s are necessary for in silico investigations. For DENV-1, PDB ID 4FFT [11] and for DENV-2, the PDB ID 1AON [12] have been taken and prepared for docking with chimera program as illustrated in figure 1 and figure 2 respectively.

![4FFT not Prepared](image1)

![4FFT Prepared](image2)

Figure 1: Structure of 4FFT and its prepared form for docking by Chimera program
Molecular Docking With Serotypes Structures
Serotypes DENV 1 and 2 were docked at their (predicted) binding sites using Autodock 4.2 tool [13].

RESULTS
BINDING SITES
The binding sites of the proteins were predicted by using the CASTp webservice. For DENV-1 with PDB ID 4FFT, the binding sites predicted are – VAL320, PHE337, SER338, THR339, ARG350, LEU351, ALA369, GLU370, PRO371, PRO372 and ILE378. For DENV-2, with PDB id 1AON, the predicted binding sites are ALA35, ASN37, LYS38, LEU294, MET297, MET301, LYS334, ILE335, PRO336, PHE337, GLU338, ILE339, ARG350, LEU351, VAL354, ASN355, PRO356, ALA369, ILE379, GLY381 and GLN386.

MOLECULAR DOCKING
For Molecular Docking on Autodock 4.2 tool the grid box value for DENV-1 protein taken are X-40, Y-60 and Z-56. For DENV-2 the grid box values are X-66, Y-94 and Z-52. Ellagic acid and Ferric carboxymaltose were docked against the DENV-1 and DENV-2 proteins.

Figure 3 and 4 shows the interaction of Ellagic acid with DENV-1 Protein in 2d and 3d, respectively. Figure 5 and 6 shows the interaction of Ferriccarboxymaltose with DENV-1 Protein in 2d and 3d, respectively. Figure 7 and 8 shows the interaction of Ellagic acid of with DENV-2 Protein in 2d and 3d, respectively. Figure 9 and 10 shows the interaction of Ferric carboxymaltose with DENV-2 Protein in 2d and 3d, respectively.

Figure 2: Structure of 1AON and its prepared form for docking by Chimera program
Figure 4: Shows the interaction of Ellagic acid with DENV-1 Protein in 3d

Figure 5: Shows the interaction of Ferriccarboxymaltose with DENV-1 Protein in 2d

Figure 6: Shows the interaction of Ferriccarboxymaltose with DENV-1 Protein in 3d
Figure 7: Shows the interaction of Ellagic acid of with DENV-2 Protein in 2d

Figure 8: Shows the interaction of Ellagic acid of with DENV-2 Protein in 3d

Figure 9: Shows the interaction of Ferric carboxymaltose with DENV-2 Protein in 2d
Figure 10: Shows the interaction of Ferric carboxymaltose with DENV-2 Protein in 3d

Table 1 and Table 2 give the docking results.

Table 1 indicates that Ellagic acid has a marginally greater binding affinity than Ferric carboxymaltose against DENV-1 @ -6.02 kcal/mol.

Table 2 indicates that Ferric carboxymaltose has a marginally greater binding affinity than Ellagic acid against DENV-2 @ -6.9 kcal/mol.

**Table 1: Docking Study of Ellagic Acid and Ferric Carboxymaltose with DENV 1 Protein (PDB ID- 4FFY)**

| Sl. No. | PubChem CID | Drug                | Binding Energy (Kcal/Mol) | Ligand Efficiency | Internal Energy | No. of H-Bonds | H-Bond Forming Residues | Average Distance of H-Bonds (Å) |
|---------|-------------|---------------------|--------------------------|-------------------|-----------------|-----------------|-------------------------|---------------------------------|
| 1.      | 5281855     | Ellagic Acid        | -6.02                    | -0.27             | -7.21           | 5               | THR339, ARG350, GLN347, GLU370 | 2.449968                         |
| 2.      | 86278165    | Ferric carboxymaltose | -5.9                   | 0.0               | -8.47           | 8               | LYS334, PHE337, ARG350, ILE352, LEU351, ALA354, ASN355 | 2.4700875                       |

**Table 2: Docking Study of Ellagic Acid and Ferric Carboxymaltose with DENV 2 Protein (PDB ID- 1OAN)**

| Sl. No. | PubChem CID | Drug                | Binding Energy (Kcal/Mol) | Ligand Efficiency | Internal Energy | No. of H-Bonds | H-Bond Forming Residues | Average Distance of H-Bonds (Å) |
|---------|-------------|---------------------|--------------------------|-------------------|-----------------|-----------------|-------------------------|---------------------------------|
| 1.      | 5281855     | Ellagic Acid        | -6.63                    | -0.3              | -7.83           | 5               | ALA35, THR40, GLU13, ASN37 | 2.597082                         |
| 2.      | 86278165    | Ferric carboxymaltose | -6.9                   | 0.05              | -6.2            | 5               | ILE339, LEU351, GLY349, GLU338 | 2.694988                         |

**DISCUSSION**

Dengue fever is a worldwide arboviral virus spread by Aedes mosquitoes that affects an estimated 2.5 billion people and is a fast expanding public health issue. Each year, there are between 50 and 100 million illnesses, with approximately 500,000 patients being admitted to hospitals with serious and life-threatening conditions [14]. The virus causes various symptoms in persons of various ages. It is minor in adults but dangerous in children and teenagers. The virus exists in four different forms in the world (DENV1, DENV2, DENV3, DENV4) [15]. The evaluated genes in this study belong to the first two types of this virus called DENV-1 and DENV-2. PDB ID for DENV-1 is 4FFT and for DENV-2 is IAON.

Type-A cellulose-binding modules (CBMs), which are components of modular cellulases, bind to crystalline cellulose and improve enzyme performance. EXLX1, a bacterial expansin with the potential to loosen plant cell walls, was studied for cellulose binding. EXLX1 has a considerable affinity for crystalline cellulose through D2, but not for soluble cellobiose oligosaccharides. Calorimetry revealed that cellulose binding was predominantly entropic. The crystal structures of EXLX1 complexed with cellulose-like oligosaccharides were solved, and we discovered that EXLX1 binds the ligands via hydrophobic interactions between three linearly organized aromatic residues in D2. The oligosaccharide was sandwiched between two D2 domains with opposing polarity, revealing a new kind of ligand-mediated dimerization [16].
Chaperonins help with protein folding by consuming ATP. They occur as multi-subunit protein assemblages made up of stacked rings of subunits. GroEL, asymmetric intermediates are generated in Escherichia coli using the co-chaperonin GroES and nucleotides attached to only one of the seven-subunit rings (the cis ring) rather than the opposite ring (the trans ring). The GroEL-GroES-(ADP)7 complex structure illustrates how bound GroES can stabilize a folding chamber with ADP confined to the cis ring via substantial en bloc motions of the cis ring’s intermediate and apical domains. The apical domains’ elevation and twist double the volume of the central cavity and bury hydrophobic peptide-binding residues at the GroES interface and between GroEL subunits, resulting in a hydrophilic cavity lining that promotes protein folding. The inward tilt of the cis equatorial domain generates an outward tilt of the trans ring, which prevents a second GroES from binding. This negative allosteric mechanism, when paired with recent functional discoveries, proposes a model for an ATP-driven folding cycle that requires a double toroid [17]. We identified best pocket of these targets and select best chain for docking. Chain A it’s our choice in both of them.

CONCLUSION

Between DENV -1 & DENV-2, serotype-1 is more pathogenic. Against it, either compound involves a very large swath of amino acid residues. Although either compound is very different on all parameters, they score closely, which posits them as complementing either compound is very different on all parameters, which posits them as complementing

ACKNOWLEDGEMENT

We stand on the broad shoulders of the very many workers pre to us who all have done pioneering works.

Declarations of interest: Authors declared that they have no conflict of interest and no financial support.

NOTE – i: Is a veritable & deep domain of supporting historical data; collateral information and references thereof. Visit: SUPPLEMENTARY FILE.

REFERENCES

1. ICTV Report. (2020). Rebecca Rico-Hesse, edited. Flaviviridae Taxonomy, https://talk.ictvonline.org/ictv-reports/ictv_online_report/positive-sense-rna-viruses/w/Flaviviridae.London.
2. Gubler, D. J., & John, A. S. (2014). Dengue viruses.
3. Yung, C. F., Lee, K. S., Thein, T. L., Tan, L. K., Gan, V. C., Wong, J. G., … & Leo, Y. S. (2015). Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, Singapore. The American journal of tropical medicine and hygiene, 92(5), 999.
4. Ekins, S., Mestres, J., & Testa, B. (2007). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British journal of pharmacology, 152(1), 9-20.
5. Behera, S. K., Mahapatra, N., Tripathy, C. S., & Pati, S. (2021). Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor–binding domain: An in silico approach. The Indian journal of medical research, 153(1-2), 132.
6. Bhattacharya, D. (2004). PunicaGranatum’s Dermis indicates Prophylaxis against Malaria & wide spectrum anti-viral property in Human use. American Journal of Tropical Medicine and Hygiene, 171(4), 288. http://www.ajtmh.org/content/71/4_supp/225.full.pdf
7. Bhattacharya, D., Ay, P. M. M., Mishra, D., Sethy, K. C., Sharma, J., Pradhan, P. K., … & Bibalani10, G. H. (2020). PUNICA GRANATUM Vrs COVID–19 Fruit to Drug. AIDS, 179, 192.
8. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … & Bourne, P. E. (2000). The protein data bank. Nucleic acids research, 28(1), 235-242.
9. Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., … & Bryant, S. H. (2016). PubChem substance and compound databases. Nucleic acids research, 44(D1), D1202-D1213.
10. Binkowski, T. A., Nagibzadeh, S., & Liang, J. (2003). CASTp: computed atlas of surface topography of proteins. Nucleic acids research, 31(13), 3352-3355.
11. Monsalve-Escudero, L. M., Loaiza-Can, V., Zapata-Cardona, M. I., Quintero-Gil, D. C., Hernández-Mira, E., Pájaro-González, Y., … & Martinez-Gutierrez, M. (2021). The antiviral and virucidal activities of voacangine and structural analogs extracted from Tabernaemontana cymosa depend on the Dengue virus strain. Plants, 10(7), 1280.
12. Friend, U. S., Parikesit, A. A., Taufik, R. I., & Amelia, F. (2009). In silico analysis of envelope Dengue Virus-2 and envelope Dengue Virus-3 protein as the backbone of Dengue Virus tetravalent vaccine by using homology modeling method. OnLine Journal of Biological Sciences, 9(1), 6-16.
13. Azam, F., Madi, A. M., & Ali, H. I. (2012). Molecular docking and prediction of pharmacokinetic properties of dual mechanism drugs that block MAO-B and adenosine A2A receptors for the treatment of Parkinson’s disease. Journal of Young Pharmacists, 4(3), 184-192.
14. Gubler, D. J. (1998). Dengue and dengue hemorrhagic fever. *Clinical microbiology reviews, 11*(3), 480-496.

15. Sankar, S. G., Sundari, T. M., & Anand, A. A. P. (2021). Emergence of Dengue 4 as Dominant Serotype During 2017 Outbreak in South India and Associated Cytokine Expression Profile. *Frontiers in cellular and infection microbiology, 11*.

16. Georgelis, N., Yennawar, N. H., & Cosgrove, D. J. (2012). Structural basis for entropy driven cellulose binding by a type-A cellulose-binding module (CBM) and bacterial expansin. *Proceedings of the National Academy of Sciences, 109*(37), 14830-14835.

17. Sigler, P. B., Xu, Z., Rye, H. S., Burston, S. G., Fenton, W. A., & Horwich, A. L. (1998). Structure and function in GroEL-mediated protein folding. *Annual review of biochemistry, 67*(1), 581-608.

**Supplementary File**

India’s national school of medicine Ayurveda (plural-life) in compendium text form is noted from c.4-5th A.D., and medicaments as (i) functional food, e.g., EA (ii) processed moieties, e.g., FC. Ayurvedic recessions and recessions are available in Sanskrit (self gelling) and in all major indo vernaculars including indo Islamic school of medicine's. Our twin moieties are indicated for ‘anemia’ (at presentation); mechanics being ‘hematnic’ (erythropoetic during therapeutic period = novel) and are noted in ‘n’ number of formulations ranging the entire indo historical period until c.1800 [S-1]. And modern medicine have robust heritage with (i) & (ii). Since >20yrs before present EA has been used by Bhattacharya vis-à-vis malaria & malignancy [S2-5]. AND FC type pre cursers of Fe (& other metals) ashes as powders & liquid in fixed has been used in anemia; geriatric care; solid - liquid cancers; metastasis; bone marrow suppression; all stages of malignancy including prophylaxis; palliative; end of life stage care; anti-viral and step-by-step drug making process enumerated in public domain [S 6-10]. Such academic treatments are not noted in any other schools of medicine [S 11:12].

**References to the Supplementing Note**

1. *Indian Jor of History of Sciences*, 2009. Indian National Science Academy, ND, 49(3), 293-297.

2. CSIR, *Compendium of Indian Medicinal Plants*: Central Drug Research Laboratory, Lko, Vol – 1, 1990-1995, p. 335, Vol – 2, 1993, p.573, Vol – IV, p. 611, Vol –5, p. 709. (preceded by Glossary AND earlier by RRL-CSIR, Bhurbaneswar publication – 3 Vols).

3. Seeram, N., Lee, R., Hardy, M., & Heber, D. (2005). Rapid large scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. *Separation and purification technology, 41*(1), 49-55.

4. Dell’Agli, M., Galli, G. V., Corbett, Y., Taramelli, D., Lucantoni, L., Habluetzel, A., ... & Bosisio, E. (2009). Antiplasmodial activity of Punica granatum L. fruit rind. *Journal of ethnopharmacology, 125*(2), 279-285.

5. Bhattacharya, D. (2017). Fight Malaria at Home: Ghare Maro Malaria Social Service to Drug Discovery–Bottom Up Model: A Review. *Air Water Borne Diseases, 6*(1). doi: 10.4172/2167-7719.1000135

6. Bhattacharya, D. (2016). A Novel Anti-Metastasis and CT’s Side Effect Reducer. *Transl Med (Sunnyvale), 6*(178), 2161-1025. Doi: 10.4172/2161-1025.1000178. https://www.longdom.org/open-access/a-novel-antimetastasis-and-chemotherapys-side-effect-reducer-2161-1025-1000178.pdf

7. VAC – Vedic Anti Cancer, https://www.academia.edu/22438917/Vedic_Anti_Cancer_MODE_OF_ACTION